News
In 2024, the U.S. healthcare industry spent $6.1 billion on Pfizer’s COVID-19 therapy Paxlovid, a 6,922.8% increase from 2023 expenditure data, according to a recent study. The research, published ...
A report from industry trade group Pharmaceutical Research and Manufacturers of America (PhRMA), conducted by Ernst & Young, ...
A 25% U.S. tariff on pharmaceutical imports would increase U.S. drug costs by nearly $51 billion annually, boosting U.S.
BNCM and DELEX Pharma are proud to announce that DELEX has been officially appointed as the Spot Dealer for the newly ...
European drugmakers are urging the EU to allow higher medicine prices, warning that without stronger investment incentives, ...
2d
Zacks Investment Research on MSNRegeneron to Report Q1 Earnings: What's in Store for the Stock?Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report first-quarter 2025 results on April 29, 2025. The ...
The move will also create 12,000 new jobs across the United States, with 6,500 in construction and 1,000 at “new and expanded ...
The big pharma joined several of its peers in committing to invest billions of dollars in new and expanded manufacturing ...
ICPI WEEK 2025, a comprehensive event bringing together component and materials companies across pharmaceuticals, biotech, ...
Drugmakers have been warned that the Trump Administration is considering linking U.S. medicine prices to lower amounts paid ...
4d
Zacks Investment Research on MSNJAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play?Jazz Pharmaceuticals JAZZ and Harmony Biosciences HRMY have emerged as notable players in the neuroscience space, especially in the sleep disorder segment. Jazz Pharmaceuticals markets multiple ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results